Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 1;23(8):105.
doi: 10.1007/s11886-021-01538-8.

Primary Aldosteronism: a Continuum from Normotension to Hypertension

Taweesak Wannachalee  1   2 , Adina F Turcu  3
Affiliations
Review

Primary Aldosteronism: a Continuum from Normotension to Hypertension

Taweesak Wannachalee et al. Curr Cardiol Rep. .

Abstract

Purpose of review: Primary aldosteronism (PA) is the most common cause of secondary hypertension. Emerging evidence suggests that PA is associated with cardiovascular, metabolic, and renal complications, that likely develop insidiously, due to prolonged inappropriate mineralocorticoid receptor activation. In this review, we discuss the expanding clinical and pathological spectrum of PA.

Recent findings: Clinical and molecular studies conducted over the recent years reveal that PA traverses a series of contiguous stages. Pre-clinical, but hormonally overt PA has been identified in patients with normal blood pressure, and such patients harbor an increased risk of developing hypertension. Similarly, genetic and histopathological advancements have exposed a spectrum of PA pathology that corresponds to a continuum that spans from pre-clinical stages to florid PA. PA evolves from pre-hypertensive stages to resistant hypertension, along with serious cardiovascular and renal consequences. Early recognition of PA and targeted therapy will be essential for cardiovascular morbidity and mortality prevention in a large number of patients.

Keywords: Adrenal; Aldosterone; Hypertension; Primary aldosteronism; Renin; Secondary hypertension.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3–17. - PubMed
    1. Conn JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med. 1956;97(2):135–44. https://doi.org/10.1001/archinte.1956.00250200011001 . - DOI - PubMed
    1. Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT. Incidence of primary aldosteronism uncomplicated “essential” hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA. 1968;205(7):497–502. https://doi.org/10.1001/jama.205.7.497 . - DOI - PubMed
    1. Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med. 1967;66(6):1079–90. https://doi.org/10.7326/0003-4819-66-6-1079 . - DOI - PubMed
    1. • Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061 These are the current Endocrine Society guidelines for PA screening, diagnosis, and treatment. - DOI - PubMed

Publication types

LinkOut - more resources